Conferences - Results from #120

Viewing 121-140 of 11775 articles

ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304)

ESMO 2024: Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy

ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate plus Prednisone for Hispanic/Latinoand Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer and Deleterious Homologous Recombination Repair Alterations

ESMO 2024: A New Prognostic Model of Overall Survival (OS) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

ESMO 2024: NEOTAX: A Phase II Trial of Neoadjuvant Toripalimab plus Axitinib for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

ESMO 2024: Real-World Characteristics and Outcomes in Patients with Muscle-Invasive Urothelial Carcinoma Treated with Adjuvant Nivolumab with or Without Neoadjuvant Chemotherapy

ESMO 2024: Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically for High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC): Interim Analysis of a Phase I Study

ESMO 2024: First Preliminary Results of Artificial Intelligence Generated Treatment Recommendations for Urothelial Cancer Based on Multidisciplinary Cancer Conferences from the KITTU Project

ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore

ESMO 2024: Targeting Epigenetic Pathways

ESMO 2024: STAR-EV: Stereotactic Treatment with Neoadjuvant Radiotherapy and Enfortumab Vedotin: A Phase I/II Study for Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer

ESMO 2024: Similar Genetic Profile in Early and Late Stage Urothelial Tract Cancer Suggests That Early Genomic Testing Bears the Potential of Timely Personalized Treatment in Clinical Trials

ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE

ESMO 2024: A Phase II Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder

ESMO 2024: Invited Discussant: RAPSON: Open-Label, Multicenter Randomized Trial of Radium-223 and Adding Metformin to ADT for Patients with mHSPC

ESMO 2024: Invited Discussant: Phase 3 ARANOTE Trial, Phase 3 Evaluation of Transdermal Estradiol vs LHRH Agonists and Ancillary Study of the PEACE-1

ESMO 2024: Systemic Treatment Options

ESMO 2024: Is There a Role for Radiation Therapy in Advanced RCC?

ESMO 2024: Efficacy and Safety of Darolutamide plus ADT in Patients with mHSPC from the Phase 3 ARANOTE Trial

ESMO 2024: Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial

2
3
4
5
6
7
8
9
10
11